1. Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line
- Author
-
Yasuto Akiyama, Ken Yamaguchi, Ryota Kondou, Takashi Sugino, Kenichi Urakami, Yoko Nakasu, Nakamasa Hayashi, Akira Asai, Chizu Nonomura, Koichi Mitsuya, Haruo Miyata, Akira Iizuka, and Tadashi Ashizawa
- Subjects
Male ,STAT3 Transcription Factor ,0301 basic medicine ,Cancer Research ,Combination therapy ,Antineoplastic Agents ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Cell Line, Tumor ,Temozolomide ,Genetics ,medicine ,Animals ,Humans ,Exome ,Chitinase-3-Like Protein 1 ,U87 ,STAT3 ,Protein Kinase Inhibitors ,Molecular Biology ,IC50 ,PI3K/AKT/mTOR pathway ,Cell Proliferation ,Oxadiazoles ,biology ,Chemistry ,TOR Serine-Threonine Kinases ,High-Throughput Nucleotide Sequencing ,Dacarbazine ,Blot ,Disease Models, Animal ,030104 developmental biology ,Drug Resistance, Neoplasm ,Cell culture ,030220 oncology & carcinogenesis ,Quinolines ,biology.protein ,Cancer research ,Glioblastoma ,Research Article ,Signal Transduction ,medicine.drug - Abstract
Background Temozolomide-resistant (TMZ-R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed. Materials and methods The efficacy of a combination treatment of STAT3 inhibitor, STX-0119, with rapamycin was investigated against our established TMZ-resistant U87 cell line. Results The growth-inhibitory effect of the combination treatment was significant against the TMZ-R U87 cell line (IC50: 78 μM for STX-0119, 30.5 μM for rapamycin and 11.3 μM for combination of the two). Western blotting analysis demonstrated that the inhibitory effect of STX-0119 on S6 and 4E-BP1 activation through regulation of YKL-40 expression occurred in addition to the inhibitory effect of rapamycin against the mTOR pathway. Conclusion These results suggest that the STAT3 pathway is associated with the mTOR downstream pathway mediated by YKL-40 protein, and the combination therapy of the STAT3 inhibitor and rapamycin could be worth developing as a novel therapeutic approach against TMZ-resistant relapsed gliomas.
- Published
- 2017